article thumbnail

Utilization of Treatment for Chlamydia and Gonorrhea in the Primary Care Setting Using the American Family Cohort [Infectious diseases (not respiratory tract)]

Annals of Family Medicine

Study Design and Analysis: A retrospective cohort from 2018-2022. Setting or Dataset: Electronic health records from the PRIME Registry, years 2018-2022. The electronic health records are stored in the American Family Cohort, the largest national United States primary care database. treatment rates, respectively.

article thumbnail

Position Statement on Measurement Based Care

Integrated Care News by CFHA

The full process of MBC (Collect, Share, and Act) supports a shared decision-making framework that is inherently therapeutic, with the aim of improving treatment outcomes as well as promoting the overall wellness of individuals and populations. (2, 1, 8, 9) d. Artificial Intelligence), etc. Lambert, M. Whipple, J. L., & Kleinstäuber, M.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Treatment of Chlamydia and Gonorrhea in Primary Care and Its Patient-Level Variation: An American Family Cohort Study [Original Research]

Annals of Family Medicine

METHODS We used electronic health records from the PRIME registry to identify patients with diagnosis codes or positive test results for chlamydia and/or gonorrhea from 2018 to 2022. We examined how well chlamydia and gonorrhea treatment in primary care settings adhered to guidelines. of these cases, respectively, were treated.

article thumbnail

Mastering Responses to FDA 510(k) AI Letters: A Strategic Approach

FDA Law Blog

Performance Metric FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 Average Number of FDA Days to MDUFA IV Decision 72.62 if additional testing is required or justification would suffice), responsible individuals, proposed timelines, and any clarifying questions for FDA. Average Number of Industry Days to MDUFA IV Decision 54.69

article thumbnail

FDA Publishes Draft Guidance on Voluntary Malfunction Summary Reporting Program for Medical Devices

FDA Law Blog

Generally, FDA’s MDR regulations require device manufacturers to submit Medical Device Reports (MDRs) for individual reportable malfunctions within 30 calendar days of the manufacturer becoming aware of the malfunction. In August 2018, FDA published a notice in the Federal Register granting an alternative under 21 C.F.R.

Medical 59
article thumbnail

Time to stop driving? Podcast with Emmy Betz and Terri Cassidy

GeriPal

Eric: For those of you don’t know, Emmy was on our podcast back in 2018 … man, pre-COVID times. That’s where it really gets to this individual risks and balances, individual situation. Emmy: But we do see individuals with beginning stages of cognitive impairment where they pass our evaluation.

IT 102
article thumbnail

Pragmatic Trial of ACP: Jennifer Wolff, Sydney Dy, Danny Scerpella, and Jasmine Santoyo-Olsson

GeriPal

And is it at all individualized to the patient? Danny 12:07 I don’t know how individualized it is. So we have to collect what information we have available from Health Information exchange and electronic health records. Sydney 22:01 Well, it’s what’s in the electronic health record. It’s a lot.